Amanote Research
Register
Sign In
Pcn151 - Cost-Effectiveness Analysis of Regorafenib in the Treatment of Patients With Hepatocelullar Carcinoma Previously Treated With Sorafenib in Portugal
Value in Health
- United Kingdom
doi 10.1016/j.jval.2018.09.234
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Date
October 1, 2018
Authors
S. André
A. Graça
V. Soares
Publisher
Elsevier BV
Related search
Successful Treatment of Hepatocellular Carcinoma With Regorafenib After Sorafenib-Induced Hypersensitivity
Internal Medicine
Internal Medicine
Medicine
Cost Effectiveness of Regorafenib as Second-Line Therapy for Patients With Advanced Hepatocellular Carcinoma
Cancer
Cancer Research
Oncology
Pcn336 - Treatment of Metastatic Castration-Resistant Prostate Cancer Patients Previously Treated With Docetaxel in Portugal
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn138 - Cost-Effectiveness Analysis of Pembrolizumab in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Cancer in England
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn141 - Cost-Effectiveness Analysis of Obinutuzumab for the Treatment of Patients With Previously Untreated Advanced Follicular Lymphoma in Greece
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Pcn168 - Cost-Effectiveness of Sorafenib in the Treatment of Hepatocellular Carcinoma: A Systematic Review
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Attenuation of Liver Stiffness in Sorafenib-Treated Patients With Advanced Hepatocellular Carcinoma
Hepatoma Research
Cost-Utility Analysis of Bosutinib for Previously Treated Chronic Myeloid Leukemia (Cml) in Portugal
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Sorafenib and Regorafenib in HBV- Or HCV-positive Hepatocellular Carcinoma Patients: Analysis of RESORCE and SHARP Trials
Digestive and Liver Disease
Hepatology
Gastroenterology
